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Abstract
Histone deacetylase inhibitors (HDACi) have therapeutic effects in models of various renal diseases including acute
kidney injury (AKI); however, the underlying mechanism remains unclear. Here we demonstrate that two widely tested
HDACi (suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA)) protect the kidneys in cisplatin-induced AKI
by enhancing autophagy. In cultured renal proximal tubular cells, SAHA and TSA enhanced autophagy during cisplatin
treatment. We further verified the protective effect of TSA against cisplatin-induced apoptosis in these cells. Notably,
inhibition of autophagy by chloroquine or by autophagy gene 7 (Atg7) ablation diminished the protective effect of
TSA. In mice, TSA increased autophagy in renal proximal tubules and protected against cisplatin-induced AKI. The
in vivo effect of TSA was also abolished by chloroquine and by Atg7 knockout specifically from renal proximal tubules.
Mechanistically, TSA stimulated AMPK and inactivated mTOR during cisplatin treatment of proximal tubule cells and
kidneys in mice. Together, these results suggest that HDACi may protect kidneys by activating autophagy in proximal
tubular cells.
Introduction
Histone deacetylases (HDACs) are important players in
epigenetic regulation that catalyze the removal of acetyl
groups from ε-N-acetyl lysine residues on histones,
resulting in an increase of positive charges in histones,
tight DNA binding, and compact chromatin to repress
gene transcription1. HDACs may also deacetylate non-
histone proteins. As such, HDACs play crucial roles in
diverse biological processes and deregulation of HDACs
contributes to the pathogenesis of major diseases2. The
research of HDACs has also led to the development of
HDAC inhibitors (HDACis) therapeutic effects3. In kid-
neys, HDACis have therapeutic potentials in experimental
models of renal fibrosis4–6, acute kidney injury (AKI)7–9,
polycystic kidney disease10,11, diabetic nephropathy12,13,
and HIV-associated nephropathy14. The mechanisms
underlying the beneficial effect of HDACis in kidneys
remain poorly understood15,16.
We demonstrated dose-dependent effects of HDACi in
renal tubular cells8,17. At micromolar concentrations, sub-
eroylanilide hydroxamic acid (SAHA) induced cell death in
these cells, whereas at lower doses SAHA protected the cells
from cisplatin-induced apoptosis. Cisplatin, a potent cancer
therapy drug, has notorious side effects in normal tissues,
especially in kidneys18–22. A pathological hallmark of cis-
platin nephrotoxicity is cell injury and death in renal
tubules23. Interestingly, HDACis, including both SAHA and
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trichostatin A (TSA), may suppress cisplatin-induced tub-
ular cell apoptosis and AKI in mice7–9, but the underlying
mechanism is largely unclear.
Autophagy is a highly conserved lysosomal degradation
pathway that eliminates protein aggregates and dysfunc-
tional organelles24,25. In cellular stress, autophagy is
activated and serves primarily as an adaptive mechanism
for cell survival, whereas deregulated autophagy plays
important roles in the pathogenesis of various dis-
eases26,27. In ischemic and nephrotoxic AKI, autophagy
is induced to protect against tubular cell injury and
death28–31. The current study tested the hypothesis that
HDACis may protect kidney cells and tissues by upregu-
lating autophagy. We demonstrated that both SAHA and
TSA enhanced autophagy in renal tubular cells. TSA
further protects against cisplatin-induced injury in renal
tubular cells and AKI in mice, and notably, the protective
effects of TSA were diminished by pharmacological and
genetic inhibition of autophagy.
Results
Autophagy is induced by TSA and SAHA in renal proximal
tubular cells (RPTCs)
Treatment of RPTCs with TSA led to LC3B-II accu-
mulation, a biochemical hallmark of autophagy32 (Fig. 1a:
lanes 3, 5, 7 vs lane 1; lanes 4, 6, 8 vs lane 2). LC3B-II
accumulation was markedly increased by chloroquine, an
auto-lysosomal inhibitor32 (Fig. 1a: lanes 2, 4, 6, 8 vs lanes
1, 3, 5, 7). The effect of chloroquine appeared more in
TSA-treated cells (lane 2 vs lanes 4, 6, 8), indicating an
increased LC3B-II turnover and induction of autophagic
flux by TSA. We then examined the expression of LC3B-
II at two different time points of 8 and 20 h. There was an
early LC3B-II accumulation following 8 h of TSA treat-
ment (Fig. 1d, lane 3 vs lane 1; lane 4 vs lane 2), accom-
panied with an increased LC3B-II turnover (lanes 2, 4 vs
lanes 1, 3). Consistently, these changes were maintained at
20 h of TSA treatment (lanes 5, 6 vs lanes 1, 2). The
immunoblotting results were confirmed by densitometry
of LC3B-II signals (Fig. 1b, c, e, f). Similarly, SAHA,
another pan-HDACi, also induced autophagy in RPTC
cells as indicated by LC3B-II (Supplementary Figure 1).
We further monitored autophagic dynamics by trans-
fecting monomeric red fluorescent protein (mRFP)-green
fluorescent protein (GFP)-LC3 plasmids. In control cells,
both green GFP-LC3 and red RFP-LC3 signals were
mostly diffuse in cells (Fig. 1g, CON). Following TSA
treatment, numerous GFP-LC3 and RFP-LC3 puncta
appeared (Fig. 1g, TSA). Almost all GFP signals co-
localized with RFP, exhibiting a yellow color indicative of
autophagosomes. Notably, the acid-sensitive GFP fluor-
escence faded or disappeared upon fusion with lysosomes,
whereas the acid-insensitive RFP signals were maintained.
Therefore, a portion of RFP-LC3 puncta with no or very
weak GFP signals showed orange-red staining in over-
lapping images, which represented autolysosomes (Fig. 1g,
TSA). Quantitatively, the number of autophagosomes per
cell was increased from ~9 in control cells to ~55 in TSA-
treated cells. The number of autolysosomes per cell was
also remarkably elevated from ~2 in control to ~61 in
TSA-treated cells (Fig. 1h). We further calculated the
proportion of autolysosomes in the total number of RFP-
LC3 puncta to indicate autophagic flux32. Control cells
had a basal rate of ~17% autophagic flux, which was
increased to ~54% by TSA (Fig. 1i).
TSA enhances autophagy during cisplatin treatment of
proximal tubular cells
We further examined the effects of TSA on cisplatin-
induced autophagy in RPTC cells. Cisplatin treatment for
20 h led to a moderate yet significant accumulation of
LC3B-II (Fig. 2a, b: lanes 3, 4 vs lanes 1, 2), which was
further enhanced by TSA (lanes 7, 8 vs lanes 3, 4). LC3B-
II turnover assay in Fig. 2c also showed that control cells
had a 1.68-fold basal level of turnover, which was
increased in cisplatin-treated cells (2.08-fold) but sig-
nificantly promoted by cisplatin+TSA (2.6-fold). In the
cells expressing mRFP-GFP-LC3 (Fig. 2d–f), cisplatin
treatment increased the numbers of both GFP-LC3 and
RFP-LC3 puncta. Notably, the average numbers of
autophagosomes and autolysosomes per cell in cisplatin-
only group were ~25 and ~16, which were increased to
~58 and ~65, respectively, in the cisplatin+TSA group
(Fig. 2e). Consistently, cisplatin-induced autophagic flux
was also elevated from ~39% to ~53% by TSA (Fig. 2f),
indicating that TSA further enhances cisplatin-induced
autophagy in RPTC cells.
Inhibition of autophagy by chloroquine eliminates the
protective effects of TSA in cisplatin-treated RPTC cells
To determine the involvement of autophagy in the
protective effect of HDACi, we first compared the effects
of TSA on cisplatin-induced tubular cell apoptosis in the
absence vs presence of chloroquine. In the absence of
chloroquine, cisplatin treatment for 20 h led to ~50%
apoptosis in RPTC cells, which was partially but sig-
nificantly reduced to ~30% by TSA (Fig. 3a: without CQ,
Fig. 3b). Consistently, cisplatin-induced caspase activation
was also attenuated by TSA under these conditions
(Fig. 3c). In sharp contrast, the beneficial role of TSA
disappeared when autophagy was inhibited by chlor-
oquine. Consistent with our previous studies33,34,
cisplatin-induced apoptosis in RPTC cells was worsened
by chloroquine. Notably, in the presence of chloroquine,
TSA was unable to suppress cisplatin-induced apoptosis
and caspase activation (Fig. 3a: with CQ, Fig. 3d, e),
suggesting a role of autophagy in the cytoprotective
effects of TSA.
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The cytoprotective effect of TSA is abrogated in Atg7-KO
mouse kidney proximal tubular cells
We further compared the effects of TSA in Atg7-KO
and wild-type (WT) mouse proximal tubular cells
(MPTCs) generated in our recent work35. We verified
autophagy deficiency in Atg7-KO cells by transfecting
mRFP-GFP-LC3 (Fig. 4a–d). In control WT cells. cisplatin
induced the formation of autophagosomes and autolyso-
somes and an increase of autophagic flux. TSA activated
autophagy on its own, and importantly, it further pro-
moted cisplatin-induced autophagy in WT MPTC cells
(Atg7 WT, TSA, CIS+TSA). However, these autophagic
responses were remarkably impaired in Atg7-KO MPTC
cells (Fig. 4a–d, Atg7 KO). GFP-LC3 puncta were rarely
seen in these knockout (KO) cells. Under both control
and cisplatin-treated conditions, the numbers of RFP-LC3
puncta and autophagic flux rate were largely reduced in
Atg7 KO cells as compared with WT cells. Furthermore,
the autophagy-stimulating effects of TSA (either used
alone or with cisplatin) were also abrogated in Atg7 KO
cells. These morphological observations were further
confirmed by immunoblot analysis of ATG7 and LC3B
(Fig. 4e, f). In WT cells, cisplatin induced a ~1.7-fold
LC3B-II accumulation, which was further increased to
~2.7-fold by TSA. By contrast, there was no detectable
ATG7 expression in Atg7 KO cells, and as a result, the
conversion of LC3B-I to LC3B-II was almost completely
attenuated.
We next examined the effects of autophagy deficiency in
Atg7 KO MPTC cells on cisplatin-induced apoptosis. Both
Fig. 1 Autophagy is induced by TSA and SAHA in renal proximal tubular cells. a–c RPTC cells were incubated with at the indicated
concentrations for 20 h in the absence or presence of 20 μM chloroquine. d–f RPTC cells were treated with 0.1 μM TSA for 8 h or 20 h in the absence
or presence of 20 μM chloroquine. After treatment, whole-cell lysates were collected for immunoblot analysis of LC3B. β-Actin was probed as a
loading control. a, d Representative immunoblot. b, c, e, f Densitometric analysis of LC3B signals. After normalization with β-actin, the protein signal
of control was arbitrarily set as 1, and the signals of other conditions were normalized with control to calculate fold changes. Data are expressed as
mean ± SD. *P < 0.05, significantly different from the control group. ^P < 0.05, significantly different from without chloroquine g–i RPTC cells were
transiently transfected with mRFP-GFP-LC3 and then treated with 0.1 μM TSA for 20 h. After treatment, cells were fixed with 4% paraformaldehyde for
fluorescence microscopy. g Representative images showing GFP-LC3 and mRFP-LC3 puncta in transfected cells (×630). Scale bar: 15 μm. h
Quantitative analysis of GFP-LC3 and RFP-LC3 puncta. Data are expressed as mean ± SD. *P < 0.05, significantly different from the control group. ^P <
0.05, significantly different from GFP-LC3 puncta counting. i Analysis of autophagic flux rate. Data are expressed as mean ± SD. *P < 0.05, significantly
different from the control group
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WT and Atg7-KO cells had minimal apoptosis under
control conditions or TSA-only treatment (Fig. 5a, b).
Cisplatin induced ~30% apoptosis in WT cells, which was
reduced to ~16% by TSA. Notably, cisplatin induced ~46%
apoptosis in Atg7 KO cells, which was only slightly sup-
pressed by TSA to 41% (Fig. 5a, b), indicating the protective
effects of TSA were abolished in Atg7 KO cells. By calcu-
lation, the inhibitory efficiency of TSA was 46% in WT cells
and 11% in ATG7 KO cells (Fig. 5c). Consistently, TSA
significantly suppressed caspase activation during cisplatin
treatment in WT cell, but it was much less effective in
Atg7-KO cells (Fig. 5d, e). Together with the choloquine
results, these data provide convincing evidence that
autophagy plays a critical role in the cytoprotective role of
TSA.
TSA enhances renal tubular autophagy during cisplatin
treatment in mice
We then examined the effects of TSA on tubular
autophagy in a mouse model of cisplatin-induced AKI. As
previously33,34, a single dose of cisplatin at 30 mg/kg
induced a persistent upregulation of LC3B-II in kidneys
for up to 4 days (Fig. 6a: lanes 2, 4, 6 vs lane 1). TSA daily
injection at 1 mg/kg further enhanced LC3B-II accumu-
lation in cisplatin-treated C57Bl/6 mice (Fig. 6a: lanes 3, 5,
7 vs lanes 2, 4, 6). These results were substantiated by
densitometric analysis of LC3B-II signals (Fig. 6b).
Autophagy induction by cisplatin was further shown by
immunohistochemical staining of LC3B (Fig. 6c), which
showed a granular, punctate staining in proximal tubule
cells during cisplatin treatment. Of note, TSA further
Fig. 2 TSA enhances autophagy during cisplatin treatment of renal proximal tubular cells. a–c RPTC cells were untreated or treated for 20 h
with cisplatin (20 μM), TSA (0.1 μM), or cisplatin+TSA in the absence or presence of 20 μM chloroquine. The cells were then collected for immunoblot
analysis of LC3B. β-Actin was used as a loading control. a Representative immunoblots. b, c Densitometric analysis of LC3B signals. Data are expressed
as mean ± SD. *P < 0.05, significantly different from the control group. #P < 0.05, significantly different from the cisplatin-only group. ^P < 0.05,
significantly different from the corresponding group without chloroquine. d–f RPTC cells were transiently transfected with mRFP-GFP-LC3 and then
treated as indicated. After treatment, cells were fixed with 4% paraformaldehyde for fluorescence microscopy. d Representative images showing GFP-
LC3 and mRFP-LC3 puncta in transfected cells (×630). Scale bar: 15 μm. e Quantitative analysis of GFP-LC3 and RFP-LC3 puncta. Data are expressed as
mean ± SD. *P < 0.05, significantly different from the control group. #P < 0.05, significantly different from the cisplatin-only group. ^P < 0.05,
significantly different from GFP-LC3 puncta counting. f Analysis of autophagic flux rate. Data are expressed as mean ± SD. *P < 0.05, significantly
different from control group. #P < 0.05, significantly different from the cisplatin-only group
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enhanced LC3B punctate staining in both numbers and
intensity. Quantitatively, the number of LC3B-positive
puncta per proximal tubule was increased from ~4 in
saline control kidneys to ~10 in cisplatin-treated mice and
further to ~23 in the cisplatin+TSA group (Fig. 6d). To
determine the dynamic changes of autophagy in kidneys,
we tested the autophagy reporter mouse model that
expresses the CAG-RFP-GFP-LC3 transgene36. As shown
in Fig. 6e, the majority of renal tubules in control kidneys
had few GFP-LC3 puncta, while a small percentage of
tubules had RFP-LC3 puncta at relatively low intensity at
the apical side toward the lumen. Cisplatin treatment led
to increases in the numbers of both GFP-LC3 and RFP-
LC3 puncta in proximal tubules, which were further
increased by TSA. Under these conditions, the punctate
LC3 staining, particularly RFP-LC3 puncta, accumulated
intensively around the nuclei in proximal tubular cells
(Fig. 6e). We further calculated the numbers of autop-
hagosomes and autolysosomes as well as autophagic flux
rate in vivo (Fig. 6f, g). Saline control mice had ~11
autophagosomes (GFP-LC3 and RFP-LC3 co-staining
puncta) per proximal tubule, which was increased to ~26
by cisplatin and further to ~48 by cisplatin+TSA. The
number of autolysosomes (RFP-LC3 puncta without GFP-
LC3 signal) per proximal tubule was also increased from
~6 in saline control to ~21 in cisplatin-treated kidneys
and further to ~70 in the cisplatin+TSA group (Fig. 6f).
Accordingly, autophagic flux rate was increased from
~31% in saline control to ~44% by cisplatin and further to
~59% by cisplatin+TSA (Fig. 6g). Together, these results
suggest that TSA promotes cisplatin-induced autophagy
in proximal tubules in mice.
Inhibition of autophagy by chloroquine abolishes the
protective effects of TSA in cisplatin-induced AKI in mice
To delineate the role of autophagy in vivo, we examined
chloroquine on the renoprotective effects of TSA in
cisplatin-treated C57Bl/6 mice. Cisplatin treatment led to
AKI as indicated by increased serum creatinine (Fig. 7a).
TSA suppressed cisplatin-induced serum creatinine from
~1.1 to ~0.7 mg/dl (CIS vs CIS+TSA). Consistenly,
cisplatin-induced tubular damage in renal cortex and out
medulla was also inhibited by TSA. Hematoxylin–eosin
(H–E) staining revealed that cisplatin induced histo-
pathological damages of kidney tissues, which were
ameliorated by TSA (Fig. 7b: CIS vs CIS+TSA). In
quantification, tubular damage score was reduced from
~3 in the cisplatin group to ~2 in the cisplatin+TSA
group (Fig. 7c: CIS vs CIS+TSA). Cisplatin also induced
caspase activation and tubular apoptosis as indicated by
cleaved caspase 3, which was also attenuated by TSA
(Fig. 7d: CIS vs CIS+TSA). However, in the presence of
chloroquine, the protective effects of TSA were com-
pletely compromised (Fig. 7a–d: CIS+CQ vs CIS+TSA
Fig. 3 Inhibition of autophagy by chloroquine eliminates the protective effects of TSA in cisplatin-treated RPTC cells. RPTC cells were
untreated or treated with cisplatin (20 μM) and cisplatin+TSA (0.1 μM) in the absence or presence of 20 μM chloroquine for 20 h. a Representative
images of cellular and nuclear morphology (×100). Scale bar: 400 μm. b, d Quantification of apoptosis percentage. c, e Caspase activity measured by
enzymatic assays using DEVD-AFC as substrates. Data in b–e are expressed as mean ± SD. *P < 0.05, significantly different from the control group. #P
< 0.05, significantly different from the cisplatin-only group
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+CQ), indicating that autophagy induction is involved in
the renoprotective effects of TSA.
The renoprotective effect of TSA in cisplatin-induced AKI is
lost in PT-Atg7 KO mice
We further determined whether the renoprotective
effect of TSA depends on autophagy by testing the con-
ditional autophagy-deficient mouse model with Atg7
specifically deleted from kidney proximal tubules (PT-
Atg7 KO)34,35. In WT control (PT-Atg7 WT) mice, cis-
platin led to LC3B-II accumulation in kidney tissues on
day 3. This upregulation of LC3B-II was further enhanced
by TSA (Fig. 8a, b: PT-Atg7 WT). In contrast, the accu-
mulation of LC3B-II were largely inhibited in PT-Atg7 KO
kidneys, indicating autophagy deficiency in these mice
(Fig. 8a, b: PT-Atg7 KO). In immunohistochemical ana-
lysis, cisplatin induced a punctate LC3B staining in
proximal tubules and the intensity of LC3B-positive
puncta was further elevated by TSA in PT-Atg7 WT
mice (Fig. 8c: PT-Atg7 WT). Quantitatively, in PT-Atg7
WT mice there were ~6 LC3B-positive puncta per tubule
in the saline control group, which was increased to ~13 by
cisplatin and further to ~23 in the cisplatin+TSA group
(Fig. 8d: PT-Atg7 WT). In contrast, PT-Atg7 KO mice
mainly showed diffuse LC3B staining in proximal tubules
(Fig. 8c, d: PT-Atg7 KO).
We further monitored kidney injury. In WT mice, cis-
platin induced increases in both serum creatinine and
blood urea nitrogen (BUN) (Fig. 9a, c: PT-Atg7 WT, CIS).
TSA partially but significantly suppressed the loss of renal
function. Serum creatinine and BUN were reduced from
1.9 and 158 mg/dl in the cisplatin group to 1.2 and 119
mg/dl in the cisplatin+TSA group, respectively (Fig. 9a, c:
PT-Atg7 WT, CIS vs CIS+TSA). Consistently, TSA also
ameliorated cisplatin-induced tubular damage in renal
cortex and out medulla, as indicated by histological
examination. Cisplatin-treated mice had a tubular damage
score of 3, which was reduced to 1.9 by TSA (Fig. 9e, f:
PT-Atg7 WT, CIS vs CIS+TSA). Cisplatin-induced cas-
pase activation was also attenuated by TSA (Fig. 9g, h: PT-
Atg7 WT, CIS vs CIS+TSA). We then determined the
effects of TSA in PT-Atg7 KO mice with impaired
Fig. 4 Autophagy is impaired in Atg7-KO mouse kidney proximal tubular cells. Wild-type (Atg7 WT) and Atg7-knockout (Atg7 KO) MPTC cells
were transiently transfected with mRFP-GFP-LC3 and then untreated or treated with cisplatin (20 μM), TSA (0.1 μM), or cisplatin+TSA for 20 h. a
Representative images showing GFP-LC3 and mRFP-LC3 puncta (×630). Scale bar: 15 μm. b, c Quantitative analysis of GFP-LC3 puncta and RFP-LC3
puncta. d Analysis of autophagic flux rate. Data in b, c, d are expressed as mean ± SD. *P < 0.05, significantly different from the control group. #P <
0.05, significantly different from the cisplatin-only group. ^P < 0.05, significantly different from the corresponding group in Atg7 WT cells. e, f Atg7 WT
and Atg7 KO MPTC cells were treated as described above without transfection. Whole-cell lysates were collected after treatment for immunoblot
analysis of LC3B and ATG7. β-Actin was used as a loading control. e Representative immunoblots. f Densitometric analysis of LC3B signals. Data are
expressed as mean ± SD. *P < 0.05, significantly different from the control group. #P < 0.05, significantly different from the cisplatin-only group. ^P <
0.05, significantly different from the corresponding group in Atg7 WT cells
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autophagy in proximal tubules. Consistent with previous
work34, PT-Atg7 KO mice developed more severe kidney
injury following cisplatin treatment than their WT lit-
termates (Fig. 9a, c, e–h: WT vs KO, CIS). Notably, TSA
only had marginal inhibitory effects on cisplatin-induced
renal function loss in PT-Atg7 KO mice (Fig. 9a, c: PT-
Atg7 KO, CIS vs CIS+TSA). The inhibition efficiency of
TSA on serum creatinine and BUN in WT mice was
25–35%, which was decreased to ~10% in PT-Atg7 KO
mice (Fig. 9b, d). Moreover, TSA did not have obvious
effects on cisplatin-induced tubular cell injury and death
in PT-Atg7 KO mice (Fig. 9e–h: PT-Atg7 KO, CIS vs CIS
+TSA). These results, together with the chloroquine test
(Fig. 7), provide compelling in vivo evidence that TSA
protects against cisplatin-induced AKI by activating
autophagy in proximal tubules.
TSA activates AMPK and inactivates mammalian target of
rapamycin (mTOR) during cisplatin treatment of RPTC cells
and C57Bl/6 mice
Autophagy involves a complex molecular machinery
that is regulated at various levels by multiple signaling
pathways24,25. To gain initial insights into the mechanism
by which TSA activates autophagy in proximal tubular
cells, we examined AMPK and mTOR, two well-
recognized autophagy regulatory pathways24,25,37. Cispla-
tin induced phosphorylation/activation of AMPK in
RPTC cells, which was accompanied with marginal inac-
tivation of mTOR as indicated by decrease in phos-
phorylated P70S6K (p-P70S6K) (Fig. 10a–c). TSA, either
used alone or with cisplatin, significantly increased p-
AMPK and decreased p-P70S6K, suggesting AMPK acti-
vation and mTOR inactivation by TSA (Fig. 10a–c).
Similar effects of TSA were observed in mouse kidney
tissues (Fig. 10d–e). These results suggest that TSA may
enhance autophagy in renal tubular cells to protect kid-
neys by activating AMPK and suppressing mTOR.
Discussion
Recent studies have demonstrated the therapeutic
effects of HDACis in several experimental models of
kidney diseases, but the underlying mechanisms remain
largely unclear. The current study has further confirmed
the protective effects of HDACi in cisplatin-induced
nephrotoxicity. Importantly, we show that TSA and
SAHA, two classical HDACis, can stimulate autophagy in
RPTCs and kidneys during cisplatin treatment. Inhibition
of autophagy either by chloroquine or by Atg7 knockout
in proximal tubular cells led to the attenuation of the
renoprotective effects of TSA, supporting a critical role of
Fig. 5 The cytoprotective effect of TSA is abrogated in Atg7-KO mouse kidney proximal tubular cells. Atg7 WT and Atg7 KO MPTC cells were
untreated or treated with cisplatin (20 μM), TSA (0.1 μM), or cisplatin+TSA for 20 h. After treatment, cells were collected for morphological and
biochemical analysis. a Representative images of cellular and nuclear morphology of apoptosis (×200). Scale bar: 200 μm. b Quantification of
apoptosis percentage. c Efficiency of apoptosis inhibition by TSA (Atg7-WT vs Atg7-KO). d Caspase activity measured by enzymatic assays. e Efficiency
of TSA reducing caspase activation (cisplatin only vs cisplatin+TSA). Data in b–e are expressed as mean ± SD. *P < 0.05, significantly different from the
control group. #P < 0.05, significantly different from the cisplatin-only group. ^P < 0.05, significantly different from the corresponding group in Atg7
WT cells
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autophagy in the protective action of TSA. Mechan-
istically, TSA stimulated AMPK and inactivated mTOR
during cisplatin treatment, suggesting that HDACis may
enhance autophagy by activating AMPK and inhibiting
mTOR, two major regulators of autophagy24,25,37.
Arany et al.7 demonstrated the cytoprotective effects of
TSA against cisplatin-induced apoptosis in mouse RPTCs.
We further verified protective effects of SAHA and TSA
in rat RPTCs8. Notably, these agents also increased cell
recovery from cisplatin cytotoxicity, indicating a long-
term pro-survival effect8. Mechanistically, we showed that
SAHA and TSA could block the DNA damage response
during cisplatin treatment, resulting in the suppression of
p53 activation, a major signaling pathway for cisplatin-
induced tubular cell apoptosis8. Ramesh and colleagues9
further revealed the anti-inflammation effects of HDACis
in cisplatin nephrotoxicityby transcriptional induction of
activated microglia/macrophage WAP domain protein.
Our current study has identified autophagy as a new
mechanism responsible for HDACi-mediated renopro-
tection during cisplatin nephrotoxicity. In our experi-
ments, both TSA and SAHA induced autophagy in
proximal tubular cells (Fig. 1, Supplementary Figure 1).
TSA further enhanced autophagy during cisplatin-
treatment of proximal tubular cells and kidneys (Fig. 2
and Fig. 6). These morphological and biochemical ana-
lyses confirmed autophagy induction and enhancement by
HDACis at steady-state levels and, more importantly,
revealed the dynamic regulation of autophagy by these
agents. To define the role of autophagy, we used both
pharmacological and genetic approaches. In cultured
proximal tubular cells, impairment of autophagy either by
chloroquine or Atg7 knockout significantly attenuated the
inhibitory effects of TSA on cisplatin-induced apoptosis
Fig. 6 TSA enhances renal tubular autophagy during cisplatin treatment in mice. C57BL/6 mice were injected with saline or a single dose of
cisplatin (30 mg/kg, i.p.) in the absence (−) or presence (+) of TSA (1 mg/kg, i.p., daily injection) (n= 7 for saline control, n= 18 for cisplatin-only, n=
20 for cisplatin+TSA). a, b Kidneys were collected at the indicated time points for immunoblot analysis of LC3B. β-Actin was used as a loading
control. a Representative immunoblots. b Densitometric analysis of LC3B signals. Data are expressed as mean ± SD. *P < 0.05, significantly different
from the saline group. ^P < 0.05, significantly different from the cisplatin-only group. c, d Kidneys were collected 3 days after treatment for
immunohistochemical staining of LC3B. c Representative images of LC3B staining (×400). Scale bar: 15 μm. d Quantitative analysis of punctate LC3B
staining. Data are expressed as mean ± SD. *P < 0.05, significantly different from the saline group. #P < 0.05, significantly different from the cisplatin-
only group. e–g CAG-RFP-GFP-LC3 mice were injected with saline or a single dose of cisplatin (30 mg/kg, i.p.) only or cisplatin+TSA (1 mg/kg, i.p.
daily) (n= 3 for saline control, n= 3 for cisplatin-only, n= 3 for cisplatin+TSA). Kidneys were collected 3 days after treatment for fluorescence
microscopy. e Representative images showing GFP-LC3 and RFP-LC3 puncta in renal tubules of CAG-RFP-GFP-LC3 mice (×630). Scale bar: 15 μm. f
Quantitative analysis of GFP-LC3 puncta and RFP-LC3 puncta. Data are expressed as mean ± SD. *P < 0.05, significantly different from the saline group.
#P < 0.05, significantly different from the cisplatin-only group. ^P < 0.05, significantly different from GFP-LC3 puncta counting. g Analysis of
autophagic flux rate. Data are expressed as mean ± SD. *P < 0.05, significantly different from the saline group. #P < 0.05, significantly different from the
cisplatin-only group
Liu et al. Cell Death and Disease  (2018) 9:322 Page 8 of 15
Official journal of the Cell Death Differentiation Association
(Figs. 3 and 5). Consistently, TSA lost its renoprotective
effects in mice when autophagy was blocked by chlor-
oquine or Atg7 ablation from kidney proximal tubules
(Figs. 7 and 9). These results unequivocally demonstrate
the importance of autophagy to the protective effects of
HDACi in cisplatin nephrotoxicity. Interestingly, impair-
ment of autophagy may also delays kidney recovery from
ischemia–reperfusion injury38, suggesting a role of
autophagy in cell or tissue recovery from injury.
A few recent studies have eluded the possible regulation
of autophagy by HDACi. Patschan et al. demonstrated that
SAHA could abrogate the autophagy inhibitory effect of
transforming growth factor-β in endothelial progenitor
cells39. Khan et al. showed that HDACi may prevent the
decline of podocyte autophagy in diabetic models and
attenuate podocyte injury as well as proteinuria40. SAHA
was also shown to increase autophagic flux in rabbit myo-
cardium and protect against ischemia/reperfusion injury41,
while TSA may promote autophagy in neurons and ame-
liorate neuronal apoptosis and brain injury induced by
subarachnoid hemorrhage in rats42. Despite these studies,
the role of autophagy in the effects of HDACis remains
unclear. Using pharmacologic and genetic inhibitory
approaches, our current study has shown convincing evi-
dence that autophagy is critical to the renoprotective effects
of HDACi in cisplatin nephrotoxicity.
Fig. 7 Chloroquine abolishes the protective effects of TSA in cisplatin-induced AKI in mice. C57BL/6 mice were divided into five groups for the
following treatment: (1) saline (n= 8), (2) a single dose of cisplatin (30 mg/kg, i.p.) only (n= 12), (3) cisplatin+TSA (1 mg/kg, i.p., daily) (n= 15), (4)
cisplatin+chloroquine (60 mg/kg, i.p., daily) (n= 6), and (5) cisplatin+TSA+chloroquine (n= 7). Blood samples and kidneys were collected 3 days
after treatment for biochemical and histological analyses. a Serum creatinine. b Representative images of kidney H–E staining (×200). Scale bar: 100
μm. c Pathological score of tubular damage. Data in a and c are expressed as mean ± SD. *P < 0.05, significantly different from the saline group. #P <
0.05, significantly different from the cisplatin-only group. &P< 0.05, significantly different from the cisplatin+TSA group. d Representative
immunoblots of cleaved caspase 3. e Densitometric analysis of cleaved caspase 3 signals. Data are expressed as mean ± SD. *P < 0.05, significantly
different from the saline group. #P < 0.05, significantly different from the cisplatin-only group. &P < 0.05, significantly different from the cisplatin with
the TSA group
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As a promising class of anticancer agents, HDACi have
synergistic or additive tumor-killing effects with many
other anticancer drugs such as cisplatin43. Using HDACi
to prevent renal damage without affecting the efficacy of
cisplatin in cancer treatment appears to be a very attrac-
tive therapeutic strategy. In this regard, our previous study
showed that SAHA, while reducing cisplatin-induced
apoptosis in kidney tubular cells, could enhance apoptosis
during cisplatin treatment of HCT116 colon cancer cells8,
supporting the possibility of in vivo use of HDACis for
renoprotection while enhancing the tumor-killing effects
of cisplatin. Although the death-promoting mechanisms
of SAHA in HCT116 cancer cells remain unclear, the
results indicate that normal cells and cancer cells may
respond differently to HDACis8. Indeed, in cancer models
of hepatocellular carcinoma, endometrial stromal sar-
coma, pancreatic cancer, and ovarian cancer, HDACis can
induce autophagy to elicit both apoptotic and non-
apoptotic cell death3. Given these findings, HDACi-
induced autophagy in normal renal tubular cells may
represent a new kidney-specific protective strategy during
cisplatin-mediated chemotherapy. Kidney tubular cells
may have significantly higher endonuclease and caspase
activities than cancer cells44,45, which may contribute to
the sensitivity of kidney tissues to HDACi protection.
The mechanisms whereby HDACis regulate autophagy
remain largely unclear. HDAC1, HDAC2, HDAC6, Sirt3,
and Sirt6 were recently shown to increase at 24 h of cis-
platin nephrotoxicity, while HDAC1, HDAC2, HDAC3,
HDAC6, Sirt3, and Sirt4 were induced at 72 h9. However,
it remains unclear which HDAC(s) mediate cisplatin
nephrotoxicity. Provided the role of HDAC in regulating
acetylation, several ATG proteins may be subjected to the
regulation by acetylation/deacetylation46,47. To under-
stand how HDACis activate autophagy in proximal tub-
ular cells, we examined the effects of TSA on AMPK and
mTOR, two well-recognized autophagy regulator. We
found that TSA could enhance AMPK activation, while
blocking mTOR activation, in cisplatin nephrotoxicity
(Fig. 10). In view of the opposite functions of AMPK and
mTOR in autophagy regulation, it is suggested that
HDACis may activate autophagy during cisplatin
nephrotoxicity at least partially through AMPK and
mTOR.
Fig. 8 Autophagy is defective in renal proximal tubules of PT-Atg7 KO mice. Wild-type (PT-Atg7 WT) and PT-Atg7 KO mice were injected with
saline or a single dose of cisplatin (30 mg/kg, i.p.) in the absence (−) or presence (+) of TSA (1 mg/kg, i.p., daily injection) (n= 5–6 for each condition).
Kidneys were collected 3 days after treatment for immunoblot analysis and immunohistochemical staining of LC3B. a Representative immunoblots.
β-Actin was loading control. b Densitometric analysis of LC3B signals. c Representative images of LC3B immunohistochemical staining (×400). Scale
bar: 15 μm. d Quantitative analysis of punctate LC3B staining. Data in b and d are expressed as mean ± SD. *P < 0.05, significantly different from the
saline group. #P < 0.05, significantly different from the cisplatin-only group. ^P < 0.05, significantly different from the corresponding groups of PT-Atg7
WT mice
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Materials and methods
Reagents and antibodies
TSA was purchased from Enzo Life Sciences. Carbo-
benzoxy-Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl
coumarin (DEVD-AFC) and 7-amino-4-trifluoromethyl
coumarin (AFC) were from Enzyme Systems Products
(Livermore, CA). Unless indicated, all other reagents
including cisplatin and chloroquine were purchased from
Sigma (St. Louis, MO). The following primary antibodies
were used: anti-LC3B from Novus Biologicals (Littleton,
CO); anti-ATG7, anti-β-actin and anti-cyclophilin B from
Abcam; and anti-cleaved caspase3, anti-AMPK, anti-
phospho-AMPK (Thr172), anti-P70S6K, anti-phospho-
P70S6K (T389) from Cell Signaling Technology (Danvers,
MA). All secondary antibodies for immunoblot analysis
were from Thermo Scientific (Rockford, IL).
Animals
C57BL/6 mice were purchased from Jackson Laboratory
(Bar Harbor, ME). Using Cre-loxP technology, a condi-
tional KO mouse model with Atg7 specifically deleted
from renal proximal tubules (PT-Atg7 KO) was recently
generated and characterized by our laboratory34,48. The
autophagy reporter mice expressing RFP-GFP-LC3
transgene under the control of a CAG promoter (CAG-
RFP-GFP-LC3 mice) were originally provided by Dr.
Joseph A. Hill at University of Texas Southwestern
Medical Center (Dallas, TX)36. All animals were main-
tained in a pathogen-free facility at Charlie Norwood VA
Medical Center under 12/12-h light/dark pattern with
free access to water and food. All animal experiments
were carried out according to a protocol approved by the
Institutional Animal Care and Usage Committee in
Charlie Norwood VA Medical Center.
Mouse model of cisplatin-induced AKI and TSA treatment
Male mice aged 8–12 weeks were used in this study. For
cisplatin injury, mice were intraperitoneally (i.p.) injected
with a single dose of cisplatin at 30 mg/kg, while control
animals were injected with a comparable volume of sal-
ine49. To test the effect of chloroquine, 60 mg/kg chlor-
oquine was injected (i.p.) 1 h prior to cisplatin
administration and then daily after cisplatin treatment. To
test the effect of TSA, 1 mg/kg TSA was injected (i.p.)
2 days prior to and daily after cisplatin administration.
Analysis of autophagy dynamics by a tandem mRFP-GFP-
LC3 reporter in transfected cells and in transgenic mice
The dynamic process of autophagy (autophagosome
formation and maturation to autolysosomes) was
Fig. 9 The renoprotective effect of TSA in cisplatin-induced AKI is lost in PT-Atg7 KO mice. PT-Atg7 WT and PT-Atg7 KO mice were injected
with saline or a single dose of cisplatin (30 mg/kg, i.p.) in the absence (−) or presence (+) of TSA (1 mg/kg, i.p., daily injection). Three days after
treatment, blood samples and kidneys were collected for biochemical and histological analyses. a Serum creatinine. b Efficiency of TSA reducing
serum creatinine (cisplatin only vs cisplatin+TSA). c BUN. d Efficiency of TSA reducing BUN (cisplatin only vs cisplatin+TSA). Data in a–d are expressed
as mean ± SD. *P < 0.05, significantly different from the saline group. #P < 0.05, significantly different from the cisplatin-only group. ^P < 0.05,
significantly different from the corresponding group of PT-Atg7 WT mice. e Representative images of kidney H–E staining (×200). Scale bar: 100 μm. f
Pathological score of tubular damage. Data are expressed as mean ± SD. #P < 0.05, significantly different from the cisplatinonly group. ^P < 0.05,
significantly different from the PT-Atg7-WT group. g Representative immunoblots. h Densitometric analysis of cleaved caspase 3 signals. Data are
expressed as mean ± SD. *P < 0.05, significantly different from the saline group. #P < 0.05, significantly different from the cisplatin-only group. ^P <
0.05, significantly different from the PT-Atg7-WT group
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analyzed in cultured proximal tubular cells expressing
mRFP-GFP-LC3 or in CAG-RFP-GFP-LC3 mice as
described in our recent work35. The rationale of this
method is that acid-sensitive GFP is quenched in the low
pH lysosomal environment, whereas acid-insensitive RFP
is more stable and maintained. Thus co-localization of
RFP fluorescence with GFP in a particle indicates an
autophagosome, and a RFP-only signal is considered an
autolysosome36,50. For in vitro experiments, cultured
proximal tubular cells were transiently transfected with
mRFP-GFP-LC3 (ptfLC3, Addgene plasmid 21074). After
treatment, the cells were fixed with 4% paraformaldehyde
for fluorescence microscopy (Zeiss 780 upright confocal
microscope). For quantitative analysis, approximately 100
transfected cells from 10 to 20 random fields (×630) were
analyzed in each condition. The numbers of GFP-LC3
puncta per cell and RFP-LC3 puncta per cell were
counted separately using ImageJ. The number of autop-
hagosomes was indicated by GFP dots and the number of
autolysosomes was obtained by subtracting GFP dots
from RFP dots. The number of autolysosomes was further
divided by the total number of RFP dots to indicate the
autophagic flux rate. For in vivo experiments, after
treatment CAG-RFP-GFP-LC3 mice were perfused fixed
with 4% paraformaldehyde. Kidneys were further fixed
overnight with the same fixative, balanced with 30%
sucrose, and embedded in Optimal Cutting Temperature
compound for cryo-section and confocal microscopy. For
each section, 8–10 fields (×630) were selected randomly
and quantitative analysis was performed by the method
described above in cultured cells.
Renal function
Renal function was determined by BUN and serum crea-
tinine measurements using commercial kits from Stanbio
Laboratory (Boerne, TX). In brief, blood samples were col-
lected for coagulation and centrifugation at room tempera-
ture to collect serum. For BUN, the reaction was conducted
at 100 °C for 12min and the absorbance at 520 nm was
recorded by the end of reaction. For serum creatinine,
samples were added to a pre-warmed (37 °C) reaction mix-
ture and the absorbance at 510 nm was monitored kineti-
cally at 20 and 80 s of reaction. BUN and creatinine levels
(mg/dl) were then calculated based on standard curves.
Histological examination
Kidney tissues were harvested, fixed with 4% paraf-
ormaldehyde, embedded in paraffin, and sectioned at 4
Fig. 10 TSA activates AMPK and inactivates mTOR during cisplatin treatment of RPTC cells and C57Bl/6 mice. a–c RPTC cells were untreated
or treated with cisplatin (20 μM) only, TSA (0.1 μM) only, or cisplatin+TSA for 20 h. After treatment, cells were collected for immunoblot analysis of p-
AMPK, AMPK, p-P70S6K, and P70S6K. β-Actin was used as a loading control. a Representative immunoblots. b, c Densitometric analysis of p-AMPK
and p-P70S6K signals after normalization with AMPK and P70S6K, respectively. Data are expressed as mean ± SD. *P < 0.05, significantly different from
the control group. #P < 0.05, significantly different from the cisplatin-only group. d–f C57BL/6 mice were injected with saline or a single dose of
cisplatin (30 mg/kg, i.p.) in the absence (−) or presence (+) of TSA (1 mg/kg, i.p., daily injection). Kidneys were collected 3 days after treatment for
immunoblot analysis of p-AMPK, AMPK, p-P70S6K, and P70S6K. β-Actin was used as a loading control. d Representative immunoblots. e, f
Densitometric analysis of p-AMPK and p-P70S6K signals after normalization with total AMPK and P70S6K, respectively. Data are expressed as mean ±
SD. *P < 0.05, significantly different from the saline group. #P < 0.05, significantly different from the cisplatin-only group
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µm. H–E staining was performed using standard proce-
dures and renal tubules with the following histopatholo-
gical changes were considered injured: loss of brush
border, tubular dilation and disruption, cast formation,
and cell lysis. Tissue damage was examined in a blind
manner and scored by the percentage of damaged tubules:
0, no damage; 1, <25%; 2, 25–50%; 3, 50–75%; 4, >75%.
Immunohistochemical staining of LC3B
Kidneys were fixed in 4% paraformaldehyde overnight
and processed for routine embedding in paraffin. After
rehydration, antigen retrieval was performed by incuba-
tion with 1 mM EDTA (pH 8.0) at 95–100 °C for 1 h. After
subsequently incubated with 0.03% H2O2 to block endo-
genous peroxidase activity and with a buffer containing
2% bovine serum albumin, 0.2% milk, 2% normal donkey
serum, and 0.8% Triton X-100 to reduce non-specific
binding, the slides were exposed to anti-LC3B antibodies
at 4 °C overnight. Negative controls were done by repla-
cing the primary antibody with antibody diluent. After
incubation with avidin–biotin blocking reagent (Vector
Laboratories, SP-2001), the slides were exposed to 1:500
biotinylated donkey anti-rabbit secondary antibody (Mil-
lipore, AP) for 1 h at room temperature. Following signal
amplification with Tyramide Signal Amplification Biotin
System (Perkin Elmer, NEL700A001KT), the sections
were incubated with a VECTASTAIN® ABC kit (Vector
Laboratories, PK-6100) and signals were developed with a
DAB kit (Vector Laboratories). For quantification of LC3B
staining, 10–20 fields (×400) were randomly selected from
each slide and the number of LC3B puncta per proximal
tubule was evaluated using ImageJ.
Cell lines
Immortalized RPTC line was originally obtained from
Dr. Ulrich Hopfer (Case Western Reserve University,
Cleveland, OH) and maintained in Dulbecco's Modified
Eagle's Medium/F-12 medium supplemented with 10%
fetal bovine serum and growth factors51. Stable floxed
control (Atg7 WT) and Atg7 KO MPTC lines (MPTC)
were generated in our recent study35. Briefly, primary
kidney proximal tubular cells were isolated from 5-week-
old Atg7-loxP mice. The cells were cultured for immor-
talization by transfecting with SV40 larger T-antigen. The
immortalized proximal tubular cells were then infected
with retroviruses expressing Cre-PURO-IRES-GFP
(pMSCV-Cre-PIG, Addgene plasmid 50395) or control
viruses to establish stable Atg7 WT and Atg7 KO cell
lines.
Cisplatin and TSA treatment of RPTCs
Cells were plated in 35-mm dishes to reach ~ 90%
confluence by next day. To induce apoptosis, cells were
incubated with 20 μM cisplatin for 20 h. TSA was given
either alone at different concentrations (0.05, 0.1, 0.2 μM)
or together with cisplatin at a concentration of 0.1 μM. In
some experiments, cells were also treated with cisplatin
and TSA in the presence of 20 μM chloroquine. After
treatment, cells were monitored morphologically or har-
vested for biochemical analyses. For cell lysis, both float-
ing and adherent cells were collected.
Examination of apoptosis
Apoptosis was examined by morphology and caspase
activity by standard methods. Morphologically, cells were
stained with 10 μg/ml Hoechst 33342 to examine cellular
and nuclear morphology by phase contrast and fluores-
cence microscopy, respectively. For each condition, four
fields with ~200 cells per field were randomly selected and
cells with typically apoptotic characterizations were
counted to estimate apoptosis percentage. To measure
caspase activity, cells were extracted with 1% Triton X-
100 and 20 μg protein were added to enzymatic reactions
containing 50 μM DEVD-AFC, a fluorogenic peptide
substrate of caspases. After 1 h incubation at 37 °C,
fluorescence was measured at excitation 360 nm/emission
530 nm. Based on a standard curve constructed with free
AFC, the fluorescence reading was converted into the
nanomolar amount of liberated AFC per mg protein to
indicate caspase activity.
Immunoblot analysis
Whole cell or tissue lysates from renal cortex and out
medulla were extracted in 2% sodium dodecyl sulfate
(SDS) buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10%
glycerol) containing protease inhibitor cocktail (Sigma-
Aldrich) and Benzonase nuclease (EMD Millipore). Pro-
tein concentration was estimated with the BCA Protein
Assay Kit (Thermo Scientific). Equal amounts of protein
were loaded in each lane and separated by SDS-
polyacrylamide gel electrophoresis. After transfer to
polyvinylidene difluoride membranes, blots were blocked
in 5% milk, probed with primary and secondary anti-
bodies, and visualized with an enhanced chemilumines-
cence kit. Either β-actin or cyclophilin B was used to
monitor protein loading and transferring.
Statistics
Qualitative data including immunoblots and cell images
are representatives of at least three experiments. Quan-
titative data were expressed as means ± SD. Statistical
analysis was conducted using the GraphPad Prism soft-
ware. Statistical differences in multiple groups were
determined by multiple comparisons with analysis of
variance followed by Tukey’s post-tests. Statistical differ-
ences between two groups were determined by two-tailed
unpaired or paired Student's t-test. P < 0.05 was con-
sidered significantly different.
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